anaplastic lymphoma kinase (ALK)

April 21, 2016April 21, 2016

Specific Non-small Cell Lung Cancer Patients Show Improvement in ARIAD’s Clinical Trial for Brigatinib

News

ARIAD Pharmaceuticals recently presented updated data from an ongoing Phase 1/2 trial testing brigatinib, an investigational tyrosine kinase inhibitor, in patients with anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC) ... Read more

April 14, 2016April 14, 2016

Phase 3 Trial of Brigatinib for Non-Small Cell Lung Cancer Linked to ALK Mutations Is Launched by ARIAD

Lung Cancer, News

ARIAD Pharmaceuticals recently announced the start of a Phase 3 clinical trial of brigatinib for locally advanced or metastatic non-small cell lung cancer (NSCLC) in adults with mutations in the anaplastic ... Read more